Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels

Molecular Imaging and Biology

Volumn 14, Issue 1, 2012, Pages 123-129

  Palomar, Azahara ^a   Nanni, Cristina ^b   Castellucci, Paolo ^b   Ambrosini, Valentina ^b   Montini, Gian Carlo ^b   Allegri, Vincenzo ^b   Pettinato, Cinzia ^b   Al Nahhas, Adil ^c   Soriano, Angel ^a   Grassetto, Gaia ^d   Rubello, Domenico ^d   Fanti, Stefano ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

CA125; Detection rate; FDG PET CT; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CA-125 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84861483125     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0468-9     Document Type: Article

References (20)

1. Poveda A, Salazar R, del Campo JM, Mendiola C, Cassinello J, Ojeda B (2007) Update in the management of ovarian and cervical carcinoma. Clin Transl Oncol 9:443-451
2. Lukanova A, Kaaks R (2005) Endogenous hormones and ovarian cancer:Epidemiology ad current hypotheses. Cancer Epidemiol Biomark Prev 14:98-107 (Pubitemid 40165289)
3. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10 (Pubitemid 30439309)
4. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
5. DiSaia P, Creasman W (2002) Epithelial ovarian cancer: clinical Gynecologic Oncology, 6th edn. Mosby, St. Louis, pp 289-350
6. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H (1991) Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103-106
7. NCCN (2010) Clinical Practice Guidelines in Oncolgy: Ovarian Cancer, including fallopian tube cancer and primary peritoneal cancer, v.2.2010. NCCN, Fort Washington
8. Bast RC, Klug TL (1983) St. John ER, Jenison E, Niloff JM, Lazarus H, et al. A radio immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887
9. Jacobs I, Bast RC (1989) The CA125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1-12 (Pubitemid 19069900)
10. Nossov V, Amneus M, Su F et al (2008) The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 99:215-223
11. Markman M (2003) Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 17:957-968
12. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC (1998) Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 70:255-258 (Pubitemid 28430939)
13. Bast RC Jr, Badgwell D, Lu Z,Marquez R, Rosen D, Liu J et al (2005) New tumour markers: CA125 and beyond. Int J Gynecol Cancer 15:274-281 (Pubitemid 43096594)
14. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS et al (2010) Preoperative Serum CA-125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer: A Meta-Analysis. J Surg Oncol 101:13-17
15. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA (1993) Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 39:2509-2513
16. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054-4057 (Pubitemid 32976692)
17. Han LY, Karavasilis V, van Hagen T, Nicum S, Thomas K, Harrison M (2010) Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer. doi:10.1016/j.ejca.2010.02.012
18. Torizuka T, Nobezawa S, Kanno T et al (2002) Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]- fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging 29:797-803
19. Garcia-Velloso MJ, Jurado M, Ceamanos C et al (2007) Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 34:1396-1405 (Pubitemid 47312579)
20. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S et al (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumour patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 104:508-515